Oramed Pharmaceuticals Inc., a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection, has received approval for a key patent by the Australian Patent Office. The patent covers an important part of the company's core technology which allows for the oral delivery of peptides. Oramed's portfolio now consists of one issued patent and 34 patents pending for its technologies and products.

Oramed's core product is an oral insulin capsule. An oral delivery system for insulin may increase patient value, leading to a healthier lifestyle, especially at the earliest of stages of diabetes treatment. Higher patient compliance may result in improved patient outcomes and a reduction in the costs of healthcare and lost productivity.

According to a report by Medtech Insight, diabetes affects nearly 24 million people in the US and an estimated 246 million adults worldwide. Being one of the most expensive diseases, it costs the US healthcare system more than $130 billion per year and the market for direct pharmaceutical care is close to $15 billion.

“Our patent position further strengthens Oramed and our competitive advantage in the development of an oral insulin capsule. The patent received will provide additional commercial protection for Oramed's technology and adds extended value to our existing IP-portfolio,” said Nadav Kidron, CEO of Oramed.